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Lung cancer (LC) is one of the most common causes of cancer-related deaths on the world and it is well 15 
known that trace elements play important roles in the carcinogenic process activating and inhibiting 
enzymatic reactions and metalloproteins, in which they usually participate as cofactors. Eleven elements 
have been included in the study: V, Cr, Mn, Fe, Co, Cu, Zn, Se, Mo, Cd, and Pb, some of them considered 
toxic (V, Cd, Cr and Pb), while others are essential (Co, Mo, Se, Fe and Zn), and they have been analyzed 
by ICP-QQQ-MS in serum, urine and for the first time in bronchoalveolar lavage fluid (BALF). In order to 20 
deepen the involvement of metal in this process, an analytical metallomic approach based on non-
denaturing precipitation of proteins (NDPP) has been optimized for the fractionation of high molecular 
mass (HMM) and low molecular mass (LMM) metal species, in order to distinguish between metal species 
that affect the biological activity and toxicological potential of the elements. In this work, the NDPP/ICP-
QQQ-MS metallomic approach has been applied for the first time to serum, urine and BALF samples from 25 
lung cancer patients and controls in order to get metal-size molecule profiles (MSMP), which can be used 
as metal-based biomarkers of altered metabolic processes  as oxidative stress and homeostasis. In this sense, 
we have demonstrated that several metals are good biomarkers when they are related to the labile ions, 
complexed with low molecular mass ligands, or in the form of metalloproteins (i.e. V and Cr in HMM and 
Cu in LMM), which has been described for the first time. On the other hand, metal dyshomeostasis 30 
biomarkers are proposed using metals ratios and correlations. Finally, ratios between elements resulted to 
be important biomarkers for lung cancer disease in serum (V/Mn, V/Pb, V/Zn, Cr/Pb), urine (Cr/Cd, Mn/Cd, 
V/Cd, Co/Cd, Cd/Pb) and BALF (V/Cu), which reflect the dyshomeostasis of metals in lung cancer disease. 
In this sense, several metals are correlated to others suggesting also the existence of an interconnected 
homeostasis in lung cancer. 35 
Keywords: Lung cancer, metal homeostasis, inter-element interactions, bronchoalveolar lavage fluid, 
serum, urine, ICP-QQQ-MS. 
 
Introduction 
Elements are essential to regular human homeostasis and play 40 
significant roles in biological systems participating in many 
cellular processes. These essential metals, which are only required 
in trace amounts, are crucial for the function of numerous enzymes 
required for fundamental biochemical processes1. For instance, 
iron is essential for the function of ribonucleotide reductase2 and 45 
zinc is a constituent of over 300 enzymes that play vital roles in 
gene expression3. Apart from their role in enzyme function, metals 
are also required for numerous biological processes such as the 
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transport of oxygen in the blood, which is mediated by hemoglobin 
containing iron4. 
Deficiency or excess of any of these elements can lead to disease 
(e.g. anemia) or deleterious toxic effects, inflammation5 and 
cancer6. As a consequence the levels of these essential metals have 5 
to be carefully balanced and a homeostatic state is maintained 
within the body5. 
On the other hand, a number of non-essential elements can also 
have important implications on human health. In this way, 
environmental exposure to arsenic, cadmium, lead and nickel has 10 
carcinogenic consequences6 due to activation of oncogenic 
signaling pathways7,8, oxidative stress6,9,10 or inhibition of DNA 
repairing system by Ni11. Many of these non-essential metals can 
also alter some enzymes function, as is the case of the competitive 
interaction of zinc and cadmium for many enzymes as consequence 15 
of their very similar atomic structure12, which has dramatic effects 
on many zinc-containing enzymes involved in important biological 
processes leading to cancer onset13. Many metals also contribute to 
cancer progression and metastasis14–18. 
Therefore, the study of the elements levels in human tissues and 20 
particularly in serum can provide interesting information about the 
changes occurring during the biological processes involved in the 
progression of diseases such as lung cancer (LC), which is the 
second most frequent cancer in humans and is the common cause 
of cancer deaths in the world19. Thus, the changes in the presence 25 
of some elements and the profiling of their chemical forms can 
reflect the status of human nutrition and metabolism and can assist 
to a possible early prediction of cancer onset and developmnent.  
There are two different points of view to relate the behavior of the 
elements in the organism during the carcinogenic process: the 30 
disturbance of the natural chemical form of the essential element 
in the metabolism due to cancer onset and progression and the 
consideration of elements involved in the carcinogenic process as 
a consequence of their high exposure. On the other hand, the 
majority of works focus on the estimation of a deficiency state or 35 
exccess and into a lesser extent about the unbalance episodes in 
which the excess of one element affects the function of other. 
However, the importance of the chemical form of elements in 
biology is well-known. Elements can be mainly present as labile 
ions or complexed with low molecular mass ligands, or in the form 40 
of metalloproteins. This difference between low molecular mass 
(LMM) and high molecular mass (HMM) species is very 
important, since it finally affects to the biological activity or 
toxicological potential of the element and their mobility across 
different biological compartments. On the other hand, the 45 
importance of metal homeostasis and metals interactions in 
biology has also been demonstrated20 and the ratio of metals 
(Cu/Zn) resulted to be different in serum and whole blood21 and 
pleural effusion22 of lung cancer patients, but the interplay of 
elements are rarely reported. 50 
Many authors have reported concentrations of essential and non-
essential elements in human biological samples from patients with 
lung cancer, such as serum21,23–25, plasma26,27, urine28,29, pleural 
efussion22 or hair24,30. In addition, there are several papers 
describing the analysis of metals in bronchoalveolar lavage 55 
fluid31,32, but they are not related with lung cancer patients. BALF 
is obtained during the exploratory study of patients with lung 
diseases and provides constituents information on cellular and 
biochemical epithelial surface of the lower respiratory tract 
through instillation and later aspiration of liquid in one or more 60 
lung segments. It is estimated that BALF samples take a million 
cells (1% of the lung surface) to yield about 1 ml of pulmonary 
secretions in the actual total recovered liquid33. Because of BALF 
is in close interaction with lung tissue is a more representative 
sample of lung status than other biofluids as blood or urine. Other 65 
authors have also classify lung cancer patients and healthy people 
using metals content in serum and hair24,30 and urine28 in order to 
use the alteration of elements for the diagnosis of LC. 
In addition most elemental determinations in several biofluids have 
been performed by techniques such as atomic absorption 70 
spectroscopy (AAS)31,34–37, particle induced X-ray emission38, 
energy dispersive X-ray fluorescence39, inductive coupled plasma 
atomic emission spectroscopy (ICP-AES)24,28,29 or inductive 
coupled plasma mass spectrometry (ICP-MS)22,26,27,30,32. The main 
advantage of using an ICP-MS equipped with a triple quadrupole 75 
is the elimination of interferences by operating in either standard 
single quadrupole (SQ) mode or tandem MS/MS. A significant 
difference is the measurement of selenium in biological samples. 
In this sense, the signal of 80Se in oxygen mode (96SeO+) would 
overlap with signals like 96Zr+, 96Mo+ or 96Ru+ in a conventional 80 
ICP-MS, but with the ICP-QQQ-MS this drawback is eliminated 
because these interferences would be rejected in the first 
quadrupole.  
The aim of this work is to propose metal based biomarkers for lung 
cancer disease in serum, urine and for the first time in BALF, using 85 
a powerful analytical tool like ICP-QQQ-MS, that has not been 
previously used in biofluids from LC patients. In addition, the 
fractionation of the blood serum for the analysis of metals in HMM 
and LMM fractions provide for the first time new contributions in 
the field of lung cancer using a procedure based on protein 90 
precipitation in non-denaturing conditions. Finally, some of these 
biomarkers are based in the homeostasis of metals using their ratios 
and correlations.  
Materials and methods 
Instrumentation 95 
Elemental analysis was performed by inductively coupled plasma 
mass spectrometry equipped with an triple quadrupole, using the 
Agilent 8800 Triple Quad (Agilent Technologies, Tokyo, Japan), 
with helium of high-purity grade ( >99.999%) and oxygen of high 
purity (>99.999%) and H2 gas. Instrumental conditions were 100 
optimized using a Tuning aqueous solution containing Li, Co, Y 
and Tl at 1µg L-1. Nickel sampling and skimmer cones were 
employed, with a sampling depth of 10 mm. The forward power 
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was set at 1550 W, and the gas flow rates were fixed at 15 L min-1 
for plasma gas and 1.08 L min-1 for carrier gas. To analyze most 
elements a flow of 4.5 mL min-1 of helium was used. For selenium, 
a flow of 2 mL min-1 of H2 with 40% of O2 was used in MS/MS 
mode. Isotopes monitored were 51V, 53Cr,55Mn, 57Fe, 63Cu, 64Zn, 5 
65Cu, 66Zn, 78Se, 80Se, 95Mo, 98Mo, 103Rh, 112Cd, 114Cd and 208Pb 
with dwell time of 0.3 s per isotope. 
A MARS microwave oven (CEM Matthrews, NC, USA) was used 
for the mineralization of samples in PFA Teflon vessels. 
Standard solutions and reagents 10 
Acetone (Trace Analysis Grade), nitric acid (purity 67-69%, Trace 
Metal Grade) and hydrogen peroxide (purity 30-35%, Optima 
Grade) were purchased from Fisher Scientific (Leicestershire, 
UK). Water was purified with a Milli-Q Gradient system 
(Millipore, Watford, UK). 15 
Blood samples were collected from lung cancer patients (LC), 
patients with non-cancerous lung diseases (NCC) and healthy 
people used as control (C), at the Pneumonology Area of Juan 
Ramón Jiménez Hospital (Huelva, Spain). The blood samples were 
obtained by venipuncture of the antecubital region, after 8 hours of 20 
fasting, and collected in BD Vacutainer SST II tubes with gel 
separator and Advance vacuum system. The samples were 
immediately cooled and protected from light for 30 minutes to 
allow clot retraction. After centrifugation (2000 g for 10 minutes) 
serum samples were frozen at -80°C until analysis. 25 
Bronchoalveolar fluid samples were obtained by instillation and 
subsequent aspiration of saline solution into one or more 
pulmonary segments or subsegments through a bronchoscope from 
patients with LC and NCC. It is not possible to obtain 
bronchoalveolar lavage samples from healthy individuals as it is 30 
an invasive technique. The resulting liquid was aliquoted into 
eppendorf tubes and stored at -80 ° C until analysis. Finally, urine 
samples were collect in sterile urine vessels and were aliquoted 
into eppendorf tubes and stored at -80 ° C until analysis. 
The study was performed in accordance with the principles 35 
contained in the Declaration of Helsinki and approved by the 
Ethical Committee from Juan Ramón Jiménez Hospital and 
University of Huelva. Table 1 showed clinical characteristics of 
patients (LC and NCC) and healthy controls (HC). In addition, all 
people gave informed consent for the extraction of peripheral 40 
venous blood and BALF. 
 
Fractionation of samples and total elements determination 
 
For non-denaturing protein precipitation of samples we used a 45 
method previously developed by the authors with some 
modifications 40. This fractionation procedure was only applied to 
serum samples since the precipitation of proteins was negligible in 
bronchoalveolar lavage fluid and urine samples. Briefly, 600 µl of 
cold acetone (-20ºC) was dropwise added to 300 µl of serum and 50 
kept for 10 min in an ice bath. The mixture was vortexed and the 
precipitate removed by centrifugation (12857 g, 4ªC, 5 min).The 
supernatant, containing LMM species, was taken to dryness under 
nitrogen stream and reconstituted in 1 ml of ultrapure water with 
0.1 µg L-1 of Rh as internal standard. On the other hand, the 55 
precipitate was subjected to microwave assisted acid digestion for 
the determination of metal content in the HMM fraction. To this 
end, the precipitate was introduced into the microwave vessel 
together with 500 µl of a mixture containing nitric acid and 
hydrogen peroxide (4:1 v/v). Mineralization was carried at 400 W, 60 
ramping the temperature to 150ºC in 10 min. Then, extracts were 
made up to 3 ml with ultrapure water, adding 0.1 µg L-1 of Rh. 
Before analysis, samples were filtered through 0.45 µm pore size 
filters of PTFE. 
The fractionation procedure was validated using an aqueous 65 
solution of bovine serum albumin standard containing Cu and Zn, 
in order to ensure the integrity of the metal protein binding during 
sample treatment as the same procedure used by Gónzalez-
Domínguez et al41. In addition, a reference material of serum and 
urine (Clinchek, Serum Control lyophylised for trace elements, 70 
level II, Recipe, and  Clinchek, Urine Control lyophylised for trace 
elements, level II, Recipe) were used to validate the analytical 
method by ICP-QQQ-MS including the reproducibility. 
Finally, total metal content of serum, urine and BALF (TOTAL) 
was determined in diluted samples previously described42. In this 75 
way, serum, urine and BALF samples were five-fold diluted with 
ultrapure water and 0.1 µg L-1 of Rh was added as internal standard 
 
Table 1. Clinical Characteristics of patients (LC and NCC) and healthy 
controls (HC) 80 
 
Samples Characteristics LC NCC HC 
SERUM 
and URINE 
Number of samples n=48 - n=39 
Age (years) 65 ± 11 - 58 ± 14 
Sex (M/W) 39/9 - 17/22 
Histology 
NSCLC 42 - - 
SCLC 6 - - 
BALF 
Number of samples n=24 n=31  
Age (years) 65 ± 13 54 ± 14 - 
Sex (M/W) 20/4 27/4 - 
Histology 
NSCLC 22 - - 
SCLC 2 - - 
DILD - 11 - 
Haemoptysis - 5 - 
Bronchiectasis - 5 - 
SPN - 3 - 
Others* - 7 - 
NSCLC: Non-small cell lung cancer, SCLC: Small cell lung cancer, 
DILD: Diffuse Interstitial Lung Disease, SPN: solitary Pulmonary 
Nodule, M: Men, W: Women, LC: Lung Cancer. *Lung Contusions 
 85 
Statistical analysis 
 
Statistical calculations were made in STATISTICA 8.0 software 
(StatSoft, Tulsa, USA). Non parametric methods were used since 
most of the variables showed a skewed distribution (checked by 90 
normal probability plots) and variances were not homogeneous 
(checked by Levene´s test). Thus, group comparison was 
conducted using Krustal-Wallis one-way analysis of variance, and 
when significance effects were observed, Mann Whitney U test 
was carried out for pairwise comparisons to find differences 95 
between groups. Only p values below 0.05 were regarded as 
statistically significant. Finally, to evaluate the specificity and 
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sensitivity of metabolites altered by the disease, ROC (receiver 
operator characteristic) curves were applied to the dataset and 
metabolites with “area under the curve” (AUC) higher than 0.75 
were considered as relevant in the progression of LC. 
 5 
Results and discussion  
 
Classification analysis using elements concentrations in urine, 
BALF, serum and serum fractions 
 10 
In this work, the total concentration of 11 elements in 87 serum 
samples, 87 urine samples and 55 BALF samples from patients 
with LC and controls (HC or NCC) were determined by ICP-QQQ-
MS. In addition, the analysis of metal content by size-fractionation 
in serum (HMM and LMM fractions) provided new contributions 15 
to the characterization of the metal profile of patients with LC.  
 
In order to establish a classification of the study groups on the basis 
of their elements concentrations, statistical discriminant analysis 
of partial least squares (PLS-DA) was performed. In addition, the 20 
weight of each variable (elements concentrations and inter-element 
ratios) of each biofluid (Total serum, HMM and LMM fractions, 
urine and BALF) in the classification (VIP value, variable 
importance on the projection) was used together with other criteria 
(see next section) for the selection of biomarkers for lung cancer 25 
diagnosis.  
 
PLS-DA is a supervised method that provides statistical models 
that allow visualizing groupings and trends between different 
groups of samples through representation of score plots.  30 
Figure 1A represents the 3D score plot of serum samples from LC 
and C groups. A clear separation of the groups can be observed 
indicating that there are elements whose concentrations are clearly 
altered in lung cancer, or maybe that when a threshold 
concentration in the body is exceeded, lung cancer is induced. 35 
  
 
 
 
Figure 1. 3D score plot obtained by PLS-DA in serum samples using the 40 
concentration of elements as variables. A) TOTAL serum, B) HMM 
fraction, C) LMM fraction. Red triangles: Cancer group, Black triangles: 
Control group. 
 
Similar graphs were constructed for urine and BALF samples 45 
(Supplementary Material, Figure 1), which give also a good 
separation between LC and HC or NCC group.  
 
In addition, the position of signals on the "loading" chart indicates 
if the element concentration is overexpressed or inhibited in lung 50 
cancer. In this way, Figure 2 shows the representation of the 
loadings plot obtained using the elements concentration in the 
HMM fraction of serum samples. Then, the signals clustered in the 
left side of the graph represent metals overexpressed in lung 
cancer, while those found in the opposite corner are reduced in 55 
these samples. Thus, the concentration of vanadium and chromium 
in the HMM of serum are higher in lung cancer patients, which 
confirm results obtained by Mann-Whitney tests. The loadings 
plots were also obtained for the concentration of elements in the 
LMM fraction of serum, serum, urine and BALF (Supplementary 60 
Material, figure 2, 3, 4 and 5). 
 
 
 
Figure 2. Loadings plot for comparison of elements concentration in the 65 
HMM fraction of serum obtained from LC and HC. 
 
Elements concentrations and ratios. Proposal of lung cancer 
biomarkers for Diagnosis 
 70 
Tables 2, 3 and 4 shows the concentration of elements in the serum 
and serum fractions, urine and BALF, respectively, as well as VIP 
values (variable importance on the projection), p-value (Mann-
Whitney U test) and AUC (“area under the curve”, ROC “Receiver 
operation curve”). Only those elements or inter-elements ratios 75 
that have a VIP value greater than 1, fold change lower than 0.5 or 
greater than 2, p-value<0.05 and AUC>0.75 (see next section) are 
included in the tables in order to select the most powerful lung 
cancer biomarkers in this paper. 
 80 
Concentration of elements for LC and HC patients in serum 
samples and serum fractions (HMM and LMM) are summarized in 
Table 2. Total levels of vanadium in serum, vanadium and 
chromium in HMM fraction of serum and copper in LMM fraction 
of serum were statistically different between LC and C and all of 85 
them were increased in LC patients from 2 to 5-fold (V-HMM).  
 
In this study, vanadium concentration was 3.77 and 5.03-fold 
higher in LC patients in serum and HMM fraction of serum, 
respectively. There is very scarce information about the role of 90 
vanadium in the body. Lin et al., analyzed vanadium in plasma 
from women with LC and found no significant differences between 
cancer and control groups26, that has also been concluded in other 
works23. On the other hand, some authors have reported the 
anticancer properties of vanadium and showed that complexes of 95 
these metals are the new metal-based drugs used in the treatment 
of several cancers, such us lung cancer43. Other authors have 
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demonstrated the influence of vanadium compounds in the 
cytotoxicity of some ligands in human lung cancer cultured cells44. 
Chromium is associated to glucose and lipid metabolism, protein 
synthesis and other important physiological functions45. 
Hexavalent form of chromium and its containing compounds are 5 
well-established lung carcinogens. Chronic exposure of the normal 
human epithelial cells is able to induce malignant cell 
transformation, the first stage of metal carcinogenesis46. 
Chromium has been previously found to be increased in serum 
samples of LC patients24,26. In this work chromium is 2.11-fold 10 
increase in the HMM of serum of LC patients. Lin et al reported an 
increase of this element in serum of LC group, but they do not 
found significant statistical differences between control and LC 
groups.  
 15 
Copper is primarily found in serum (95% as part of the oxidative 
enzyme ceruloplasmin and the remainder is present in an anionic 
form loosely bound to albumin47. Copper, zinc and manganese 
regulate the levels and activities of antioxidants, especially 
enzymatic ones, and the disturbed redox status may be critical to 20 
lung carcinogenesis. These metals are cofactors or ions stabilizing 
the molecular structure of superoxide dismutase (SOD), an 
endogenous antioxidant48. The concentration of copper has been 
reported to be increased in LC patients and its concentration is 
related to cancer state and localization21,23,24,26,27,35–37,47. In this 25 
study, the copper concentration in the LMM fraction of serum 
(labile copper) is 2.29-fold higher than in control patients.  
 
The main altered metal in the urine of LC patients of this study is 
cadmium (Table 3). Cadmium is recognized as a human 30 
carcinogen, a classification mainly based on occupational studies 
of lung cancer49. Cadmium levels in urine, serum and blood of 
smokers has previously proposed as a marker for the development 
and progression of lung diseases 50 and it has also found to be 
increased in the urine of cancer patients 28,29. The National Report 35 
on Human Exposure to Environmental Chemicals from the Centers 
for Disease Control and Prevention (CDC) reported a mean urine 
cadmium concentration of 0.172 µg/L (0.199 µg/g creatinine) for 
non-smokers versus 0.308 µg/L (0.336 µg/g creatinine) for 
smokers in the U.S. population (not stratified by age)51. 40 
On the other hand, lung cancer patients have manganese 
concentrations in bronchoalveolar lavage fluid 1.5-fold higher 
than control group (Table 4). Manganese superoxide dismutase 
(Mn-SOD), as a single superoxide radical scavenger in 
mitochondria, may have a big role in preventing cells as an 45 
antioxidant and tumor suppressor52. In the lungs, Mn-SOD is 
considered to be of critical importance for antioxidant defense53. A 
number of studies have defined associations between the Mn-SOD 
Ala16Val polymorphism and different cancer types54–56. Lin et al26 
found higher levels of Mn in serum from LC group according our 50 
results. In the same way, Tan et al. reported a decrease of this 
element in urine of LC patients29 . Some authors reported 
decreased levels of manganese in BALF from patients with diffuse 
lung diseases34 or in ill calves57, but there is no antecedent about 
the concentration of manganese in BALF samples from LC 55 
patients. 
 
Metal dyshomeostasis in lung cancer 
 
As has been commented, lung cancer is associated with imbalances 60 
in the levels of elements that are reflected in the results from serum, 
urine, BALF and/or fractions (Table 2, 3 and 4). In addition, the 
concentrations of elements were further analyzed to obtain inter-
element ratios in order to understand the interrelations of 
elements. Those ratios that showed significant changes between 65 
the study groups are listed in Table 2, 3 and 4 for serum, urine and 
BALF, respectively, which allows discovering the effect of 
alterations of single elements on the homeostasis of the rest in each 
level of structural organization. Good separations between LC and 
C or NCC group were also obtained using the inter-element ratios 70 
by PLS-DA in BALF (Figure 3), urine and serum samples 
(Supplementary Material, figure 6 and 7).  
 
Results obtained shows clear interactions of V with Mn, Pb and 
Zn, Cr with Pb in serum, Cd with Cr, Mn, V, Co and Pb in urine 75 
and V with Cu in BALF. Several papers describes the interactions 
between Cu and Zn, concluding that high Cu:Zn ratios are common 
in serum of patients with lung cancer21–23,58–60, but we do not find 
this interaction to be significate using VIP, p-value, AUC and fold 
change criteria. The ratio between Cd and Zn has also been found 80 
to be different between smokers and nonsmokers and it is also 
different in smokers for several diseases and cancers50. On the 
other hand, the inter-element ratios that resulted to be significative 
different in lung cancer patients against healthy people in this 
paper have not been previously described and show high values of 85 
VIP, fold changes AUC and p-value. 
 
 
 
 90 
Figure 3. A) Loadings plot for comparison of inter-element ratios in BALF 
obtained from LC and NCC. B) 3D score plot obtained by PLS-DA in 
BALF samples using the inter-element ratios as variables. Red triangles: 
Cancer group, Green triangles: Control group. 
 95 
 
 
 
 
 100 
Table 2. Total elements concentration (μg g-1) in serum samples (TOTAL) and serum fractions (HMM and LMM) 
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  V (TOTAL) 
V 
 (HMM) 
Cr 
(HMM) 
Cu  
(LMM) V/Mn V/Pb V/Zn Cr/Pb 
Medium concentration HC 0.05 0.04 0.39 33.33 0.02 0.03 0.00004 0.35 
aSEM in HC group 0.02 0.02 0.17 2.78 0.01 0.01 0.00002 0.14 
Medium concentration LC 0.18 0.19 0.83 76.29 0.08 0.14 0.00164 0.96 
bSEM  in LC group 0.04 0.05 0.12 2.58 0.01 0.02 0.00004 0.19 
Fold Change (LC/HC) 3.77 5.03 2.11 2.29 3.55 4.27 4.10 2.79 
VIP 1.82  1.72  1.89 2.08 1.427 1.472 1.50 1.641 
p-value (Mann Whitney U test) 0.000039 0.000007 0.00003  0.00000 0.000033 0.000015 0.000048 0.000026 
AUC 0.76 0.78 0.78 0.92 0.77 0.76 0.76 0.76 
aStandard error of the mean (n=39), bStandard error of the mean (n=48),  
Fold changes (Lung cancer vs healthy people), Variable importance on the projection values (VIP), p-value (statistical pairwise comparisons by Mann-
Whitney U test) and AUC values of ROC curves 
 
 5 
Table 3. Total elements concentration (μg g-1) in urine samples) 
  Cd  Cr/Cd Mn/Cd V/Cd Co/Cd Cd/Pb 
Medium concentration HC 0.67 6.38 10.62 3.83 1.56 0.09 
aSEM in HC group 0.07 1.47 1.66 0.73 0.24 0.01 
Medium concentration LC 1.55 2.33 3.95 1.6 0.42 0.23 
bSEM  in LC group 0.21 0.47 0.48 1.43 0.05 0.03 
Fold Change (LC/HC) 2.32 0.37 0.37 0.42 0.27 2.47 
VIP 1.703 1.813 2.07 1.484 1.897 1.574 
p-value (Mann Whitney U test) 0.000014 0.000006 0.000002 0.000021 0 0.000955 
AUC 0.79 0.76 0.77 0.75 0.81 0.74 
aStandard error of the mean (n=39), bStandard error of the mean (n=48),  
Fold changes (Lung cancer vs healthy people), Variable importance on the projection values (VIP), p-value (statistical pairwise comparisons by Mann-
Whitney U test) and AUC values of ROC curves 
 10 
 
Table 4. Total elements concentration (μg g-1) in bronchoalveolar lavage fluid) 
  Mn  V/Cu 
Medium concentration NCC 0.46 1.03 
aSEM in NCC group 0.06 0.10 
Medium concentration LC 0.69 0.51 
aSEM in LC group 0.09 0.11 
Fold Change (LC/NCC) 1.51 0.49 
VIP 1.29 1.22 
p-value (Mann Whitney U test) 0.003 0.01811 
AUC 0.75 0.76 
a Standard error of the mean ( (n=31), bStandard error of the mean ( (n=24) 
 Fold changes (Lung cancer vs non-cancerous control), Variable importance on the projection values (VIP), p-value (statistical pairwise comparisons by 
Mann-Whitney U test) and AUC values of ROC curves 15 
 
 
 
Table 5. Correlations between metals in biofluids and fractions (p<0.05) 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |7 
 
Moreover, Table 5 shows Spearman´s correlation coefficients 
calculated to evaluate the interdependence of metals in the 
organism, suggesting the existence of an interconnected 
homeostasis. In this sense, levels of Cr, Mn, Fe, Pb, V, Zn, Co 5 
and Se in the different biofluids and/or HMM fraction present a 
correlation coefficient among them higher than 0.5, indicating a 
possible common route for their biological regulation. Among 
these elements, Cr, Mn and V also show significate imbalances 
in the analyzed biofluids (Table 2). On the other hand, the 10 
interrelations between Cr and Pb (urine) and V and Pb (BALF) 
were also important as can be concluded by the inter-elements 
ratios (serum, Table 2).  
Other elements that are interconnected only by the correlation 
coefficients are selenium and zinc (BALF). The antioxidant 15 
properties of selenium are well-known and alterations of this 
element can be related with oxidative stress. In this work, 
selenium is positively correlated with zinc in BALF samples, 
which is implicated in glucometabolic disorders61. Cobalt and 
copper are also positively correlated in BALF. The function of 20 
cobalt in the body is to be a cofactor of vitamin B12, but in the 
form of labile ions is able to generate reactive oxygen species, 
such as copper and iron41. On the other hand, other correlations 
have not been previously described. 
 25 
Conclusions 
 
The present paper describes for the first time the use of triple 
quadrupole ICP-MS for the analysis of metals in biofluids from 
lung cancer patients and healthy people. This powerful analytical 30 
methodology has been combined with a careful approach based 
in the use of VIP values, fold changes, p-value<0.05 and AUC 
values to propose the most important lung cancer biomarkers. 
This work shows that metal contents in serum, urine and for the 
first time in BALF can be used to distinguish healthy people and 35 
lung cancer patients. In addition, several metals are good 
biomarkers when they are related to the labile ions, complexed 
with low molecular mass ligands, or in the form of 
metalloproteins (i.e. V and Cr in HMM and Cu in LMM), which 
has been described for the first time.  40 
On the other hand, taking into account the complexity of 
biological systems, some important effects may be caused by the 
interplay of more than two elements, but such interactions are 
rarely reported. Finally, ratios between elements resulted to be 
important biomarkers for lung cancer disease (in serum: V/Mn, 45 
V/Pb, V/Zn, Cr/Pb, urine: Cr/Cd, Mn/Cd, V/Cd, Co/Cd, Cd/Pb and 
BALF: V/Cu), which reflect the dyshomeostasis of metals in lung 
cancer disease. In this sense, several metals are correlated to 
others suggesting also the existence of an interconnected 
homeostasis in lung cancer.  50 
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